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MicroarrayBonemarrow stromal cells (BMSCs, also known as bonemarrow-derivedmesenchymal stemcells) and their pro-
genitors have been identiﬁed based on retrospective functional criteria. CD markers are employed to deﬁne cell
populations with distinct functional characteristics. However, deﬁning and prospective isolation of BMSCs and
committed progenitors are lacking. Here, we compared the transcriptome proﬁle of CD markers expressed
at baseline and during the course of osteoblast and adipocyte differentiation of two well-characterized
osteogenic-committedmurine BMSCs (mBMSCBone) and adipogenic-committedmBMSCs (mBMSCAdipo), respec-
tively. Bioinformatic analysis revealed the presence of a core set of canonical mBMSC CDmarkers with compara-
ble expression levels inmBMSCBone andmBMSCAdipo at baseline and during their differentiation.We identiﬁed 11
CD markers that are differentially expressed between mBMSCAdipo and mBMSCBone. Among these, we identiﬁed
osteoprogenitor-associated CDmarkers expressed only inmBMSCBone: CD34, CD54, CD73, CD132, CD200, CD227
and adipoprogenitor-associated CD markers expressed only in mBMSCAdipo: CD53, CD80, CD134, CD141 and
CD212. FACS analysis conﬁrmed these results. We selected CD34 for further analysis. CD34 was expressed at
baseline of mouse stromal cell line ST2, primary mBMSCs, mBMSCBone and its expression decreased during oste-
oblast differentiation. FACS-sorted CD34+ primary mBMSCs exhibited higher expression of 70% osteoblast-
associated genes, and formed signiﬁcantly higher heterotopic bone in vivo when implanted subcutaneously in
immune-deﬁcient mice compared with CD34− primary mBMSCs. Our results demonstrate that a set of CD
markers can distinguish osteoprogenitor versus adipoprogenitor populations of mBMSCs. CD34 is suitable for
prospective isolation of mouse bone marrow osteoprogenitors.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The stem cell subset contained within the bonemarrow stromal cell
population (BMSCs, also known as bonemarrow-derivedmesenchymal
stem cells) is characterized by self-renewal capacity, clonogenicity
in vitro, multipotent differentiation into mesoderm-type cells including
osteoblast, adipocyte and chondrocyte and their ability to form bone
and hematopoiesis-supporting stroma upon in vivo transplantation
(Abdallah et al., 2005; Mabuchi et al., 2013). BMSCs are isolated
based on adherence to the plastic surface of culture plates and the
cells exhibited cellular and functional heterogeneity in culture. Thus,y Laboratory (KMEB), Odense
K-5000 Odense C, Denmark.
ah).
. This is an open access article underunderstanding cellular mechanisms of the beneﬁcial therapeutic ef-
fects of BMSCs requires better deﬁnition of BMSCs in terms of pheno-
type and functional capacity. In this context, the minimal criteria
(suggested by Tissue Stem Cell Committee of the International Society
for Cellular Therapy) (Dominici et al., 2006) for deﬁning BMSCs are
based on a limited number of CD markers of variable sensitivity and
speciﬁcity. Thus, there is a need for identifying CD markers that deﬁne
BMSCs and their lineage committed populations. Such CD markers
will be useful to use to isolate homogenous populations of BMSCs for
clinical use.
CD surface markers have been used to isolate different popula-
tions of mBMSCs with differences in their functions. For example:
PDGFRα+Sca-1+CD45−TER119− (Morikawa et al., 2009), CD34+/
CD73+ (Akiyama et al., 2012), CD105+ (Goussetis et al., 2005),
CD271+/CD90+/CD106+ (Mabuchi et al., 2013), CD271+/CD140β+
(Buhring et al., 2007) and CD49a (Gronthos et al., 2001) have been
reported to deﬁne BMSCs. However, these markers do not distinguishthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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heterogeneity of BMSC cultures, we have employed in previous studies
a single cell cloning approach. We have demonstrated that human
BMSCs contain committed progenitors with lineage-speciﬁc osteoblast
differentiation capacity and in vivo bone forming ability (Larsen et al.,
2010). Similarly, we have isolated and characterized from mouse
BMSCs, two homogenous BMSC cell lines with unipotent differentia-
tion capacities of either osteoblasts or adipocytes: mBMSCBone and
mBMSCAdipo, respectively (Post et al., 2008). Interestingly, both cell
lines share a similar pattern of the known surface markers of BMSCs.
Thus, these cells are good models to determine surface marker expres-
sion associated with lineage commitment, using global methods of
transcriptomic analysis or proteome analysis.
In the present study, we aimed at identiﬁcation of BMSC lineage spe-
ciﬁc CD markers. We conducted a DNA microarray expression analysis
and compared the global CDmarker transcription proﬁle of mBMSCBone
andmBMSCAdipo during their differentiation course into osteoblasts and
adipocytes, respectively. Data obtained from these two homogenous
populations of mBMSCs enabled us to identify a set of CD markers
that deﬁne osteoblast progenitor and adipocyte progenitor phenotype.
Follow-up studies identiﬁed CD34 as a prospective marker suitable for
isolating homogenous population of osteoblast progenitors directly
from cultured mBMSCs with capacity for in vitro osteoblast differentia-
tion and in vivo bone formation.
2. Materials and methods
2.1. Cell culture
Isolation and phenotypic characterization of mouse bone marrow
derived spontaneously immortalized clonal cell strains mBMSCAdipo and
mBMSCBone have been described previously (Post et al., 2008). Cells
were cultured in DMEM (Gibco Invitrogen, USA) supplemented with
12% fetal bovine serum (FBS; Gibco Invitrogen, USA) and 1% penicillin/
streptomycin (P/S) (Gibco Invitrogen, USA).
Mouse stromal cell line, ST2 was obtained from Leibniz Institute
DSMZ-German Collection of Microorganisms and Cell Cultures (ACC
333, Braunschweig, Germany). Cells were cultured in DMEM supple-
mented with 10% FBS and 1% penicillin/streptomycin (P/S) (all pur-
chased from Gibco Invitrogen, USA) (Otsuka et al., 1999). Mouse bone
marrow stromal cells (mBMSCs) were isolated from wild-type 8-week-
old C57BL mice using a previously published centrifugation protocol
(Peister et al., 2004). Cells were plated at a density of 1 × 106 cells/cm2
in RPMI medium supplemented with 12% fetal bovine serum (FBS;
Gibco Invitrogen, USA) and 1% penicillin/streptomycin (P/S) (Gibco
Invitrogen, USA). After 48 h of culture, medium was removed, cells
were washed with PBS and fresh medium was added.
2.2. Adipocyte differentiation
Cells were plated at 15,000 cells/cm2 and cultured for 12 days in
adipogenic-induction medium (AIM; DMEM supplemented with 9%
horse serum, 450 μM 1-methyl-3-isobutylxanthine (IBMX), 250 nM
dexamethasone, 5 μg/mL insulin (Sigma-Aldrich) and1 μMrosiglitazone
(BRL 49653, Cayman Chemical, Ann Arbor, Michigan)). The media was
changed every three days.
2.3. Osteoblast differentiation
Osteoblastic differentiation was performed on cells plated at
15,000/cm2 for 12 days in osteoblast-induction media (OB) containing
αMEM supplementedwith 10mMbeta-glycerophosphate (Calbiochem-
Merck, Germany), 50 μg/mL L-ascorbic acid-2-phosphate (Wako
Chemicals GmbH, Germany) and 10 nM dexamethasone (Sigma-
Aldrich, Denmark). The medium was changed every three days during
induction.2.4. Ectopic bone formation in mice
To study the in vivo osteogenic capacity of sorted CD34− or CD34+
sub-populations, 5 × 105 cells were mixed with 40 mg hydroxyapatite/
tricalcium phosphate (HA/TCP) ceramic powder (Zimmer Scandinavia
Albertslund, Denmark) and implanted subcutaneously in the dorsal
surface of 2-month-old female in NOD/MrkBomTac-Prkdcscid mice
(Taconic, Ry, Denmark). Implants (n=4 implants/cell line)were recov-
ered 8 weeks after transplantation, demineralized in EDTA solution
((25% W/V), pH = 7.1), parafﬁn embedded, sectioned, and stained by
eosin/hematoxylin as described previously (Justesen et al., 2004). Four
μm sections were cut and stained with hematoxylin and eosin (H&E)
(Bie&Berntsens). The total bone volume per total volumewas quantiﬁed
as described previously (Abdallah et al., 2008).
2.5. Oil Red O staining
At day 12 of adipocyte induction, cells were ﬁxed in 4% paraformal-
dehyde for 10 min at room temperature then stained with Oil Red O
(Sigma, USA) to visualize the lipid content and droplet size. Brieﬂy,
cells were rinsed in 3% isopropanol solution and stained with ﬁltered
Oil Red O solution (0.5 g in 100% isopropanol) for 1 h at room tempera-
ture. Lipid accumulations were quantiﬁed by elution of Oil Red O in
absolute isopropanol for 10 min at room temperature. The absorbance
of the extracted dye was detected at 490 nm using a FLUO star Omega
plate reader (BMG Laboratories, Denmark).
2.6. Alkaline phosphatase (ALP) staining
Cells were ﬁxed with acetone/10 mM citrate buffer pH 4.2 (1.5:1
ratio) at room temperature for 5min and incubated for 1 h at room tem-
perature with ALP substrate staining solution containing 0.2 mg/mL
Naphthol-AS-TR-phosphate dissolved in distilled water (1:5) and
0.417 mg/mL Fast Red dissolved in 0.1 M Tris buffer.
2.7. Alizarin red S staining (AR-S)
Calcium deposition, at day 12 of osteoblastic differentiation, was
measured using Alizarin red staining. Osteoblasts were ﬁxed with 70%
ice-cold ethanol for 1 h at −20 °C before addition of AR-S (40 mM;
Sigma-Aldrich) dissolved in distilled water, pH 4.17. The cells were
stained for 10 min at room temperature. The level of calcium deposi-
tion was quantiﬁed by elution of AR-S following incubation in 10%
cetylpyridinium chloride (Sigma-Aldrich) for 1 h at room temperature.
The absorbance of the eluted dye was assessed at 570 nm in a FLU
Ostar Omega plate reader.
2.8. Microarray based gene expression analysis
mBMSCAdipo and mBMSCBone cells were cultured in triplicate under
standard culture conditions as described above and differentiated into
either adipocyte or osteoblast respectively. Total RNA were isolated at
day 0, 1, 3, 6 and 9 during differentiation course. To perform global
gene expression analysis, 500 ng quality-checked total RNA per sample
in triplicate were ampliﬁed and labeled according to the
manufacturer's protocol (Illumina TotalPrep RNA Ampliﬁcation Kit,
Ambion, Austin, TX, USA, www.ambion.com). The resulting biotinylat-
ed cRNA was puriﬁed and hybridized to MouseRef-8 v2.0 Expression
BeadChip (Illumina, San Diego, CA, USA, www.illumina.com) on the
Illumina Beadstation 500 platform, followed by washing, blocking,
staining with streptavidin-Cy3 and quantitative detection of the ﬂuo-
rescent image of the array as speciﬁed by the manufacturer. Raw
data were processed using the Gene Expression Module version 1.8.0
provided with the GenomeStudio software (Illumina). This included
background subtraction and normalization according to the ‘rank in-
variant’ algorithm. Genes were considered “expressed” if the
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pdet b0.01. Differential gene expression analysis was computed using
the ‘Illumina Custom Model’. P-values of differentially expressed genes
(‘Diff P-Values’) modiﬁed by the Benjamini and Hochberg false discov-
ery rate (FDR) correction algorithm (Benjamini and Hochberg, 1995).
Genes with 3 fold up- or down-regulated average signal intensities be-
tween the samples or groups of samples of interest were considered
“differentially expressed” genes if the corresponding FDR-adjusted
‘Diff P-Value’ padj b0.05 and provided that the gene of interest was
expressed in at least one of the samples under consideration.
2.9. Real time-polymerase chain reaction (RT-PCR)
RNA was extracted using TRIzol (Life Technologies; according to
the manufacturer's instructions) and the ﬁrst strand complementary
DNA was synthesized from 1 μg of total RNA using a Revert Aid™ H
minus ﬁrst strand cDNA synthesis kit (Fermentas, Sweden). RT-qPCR
was performed using an ABI StepOne™ Real-TIME PCR machine
(Life Technologies/Applied Biosystems) with SYBR green (Applied
Biosystems). The targeted primers and reference genes are shown in
supplementary Table 1. The data were normalized to the geometric
means of the reference genes β-actin and HPRT and analyzed using
a comparative CT method where Δ-CT is the difference between the
CT values of the target and the geometric mean of the reference
genes.
2.10. PCR array analysis
Total RNA was extracted from both sorted CD34+ and CD34‐
mBMSCs at baseline. Osteogenic RT2 Proﬁler™ PCR array, containing
84 osteoblast-related genes (Qiagen Nordic), was performed for each
sample in triplicates using SYBR® Green quantitative PCR method.
2.11. Flow cytometry for cells surface markers characterization
Cells were proﬁled for surface markers to identify their immune-
phenotype. Each cell type was single cell suspended and, incubated in
FACS buffer containing pre-conjugated antibodies (see supplementary
Table 2) for 20 min on ice. Following incubation, cells were washed
twice with FACS buffer. All the ﬂow cytometry performed using a Cell
Lab Quanta SCMPL. The data were analyzed using Kaluza®1.2 software
(Beckman Coulter, Denmark) and the expression of each CDmarkers on
the cells was calculated based on the percentage andmeanﬂuorescence
intensity (MFI).
2.12. Fluorescence activated cell sorting (FACS)
mBMSCs in cell suspension washed with PBS−/− (Life Technologies).
Cells were stained with pre-conjugated CD34-PE antibody for 20 min on
ice. Non-speciﬁc binding was blocked by incubation in FACS buffer (Life
Technologies) containing 0.5% BSA and 40 nM EDTA, (Sigma-Aldrich,
Denmark). Following incubation, the unbound antibodies were removed
using a 3 ml wash of FACS buffer. The cells were sorted into 2 separate
populations (CD34− and CD34+) using a FACS Aria™ III (BD Biosciences,
Denmark). Sorting gates were established based on the appropriate
isotype control for CD34 antibody (supplementary Table 2). The sorted
cell populations were then re-cultured for further experiments.
2.13. Alkaline phosphatase (ALP) activity assay
ALP activity was performed on at d6 of osteoblastic induction. Cell
viability was determined using the Cell Titer-Blue cell viability assay
according to the manufacturer's instructions (Promega, USA) and the
viability measured at 579Ex/584Emnm using a FLUO star Omega plate
reader (BMG Laboratories). ALP activitywas determined following incu-
bation with 1 mg/mL of P-nitro phenyl phosphate in 50 mM NAHCO3and 1 mM MgCl2 buffer (pH 9.6) at 37 °C for 20 min. The activity was
stopped by addition of 3 M NaOH. The reaction absorbance
was measured at 405 nm using a FLUO star Omega plate reader (BMG
Laboratories) and ALP activity corrected for cell viability.
2.14. Cell morphology analysis by high content imaging
Cells were seeded in 96-cell carrier well-plates (PerkinElmer,
Germany) and cultured in standard medium to assess differences in
their morphology. Following one day of culture, the adherent cells
were washed with PBS−/−, ﬁxed in 4% Paraformaldehyde for 10 min
at room temperature andwashed three timeswith PBS. Cells were incu-
bated with 1 μg/mL Alexa Fluro 568 Phalloidin (Molecular Probes, USA)
for 40 min and washed twice with PBS. For nuclear visualization, cells
were incubated in 1 μg/mL of DAPI (Sigma, USA) for 10 min at room
temperature. The imaging of the cells and all the parameters analyzed
were performed using an Operetta High Content Screening system
(Perkin-Elmer, Germany). Images were analyzed using Harmony®
High Content Imaging Software (PerkinElmer).
2.15. Statistical analysis
All experiments were performed in triplicate and at least 3 inde-
pendent experiments were conducted. The data are presented as the
mean ± SD. The statistical analysis was performed using Prism 5
(GraphPad). Student's t-test was used for comparison between two
groups and one way ANOVA was used for experiments with more
than two groups. Differences were considered statistically signiﬁcant
at *p b 0.05, ** p b 0.005 and ***p b 0.0001.
3. Results
3.1. Identiﬁcation of predictive osteoblast and adipocyte CD markers
To identify CD markers associated with MSC lineage-commitment
into osteoblasts and adipocytes, we employed the transcriptome pro-
ﬁles of two previously characterized committed osteoprogenitor and
adipoprogenitor populations derived from mBMSCs: mBMSCBone and
mBMSCAdipo, respectively (Post et al., 2008). As shown in Fig. 1A, the os-
teoblastic differentiation of mBMSCBone was evidenced by the ability of
the cells to form mineralized matrix stained positive with Alizarin red
as well as in vivo heterotopic bone. The adipogenic commitment of
mBMSCAdipo was evidenced by the ability of the cell to form mature
lipid ﬁlled adipocytes stained byOil red O and the absence of heterotop-
ic bone formation when implanted in vivo. A more detailed description
of the two cell lines have been previously published (Post et al., 2008).
Microarray based gene expression analysis was performed at different
time points during the course of osteoblast and adipocyte differentia-
tion of mBMSCBone and mBMSCAdipo, respectively. More than 80% (p b
0.005) of the up-regulated genes during osteoblast differentiation of
mBMSCBone and 60% (p b 0.005) of the upregulated genes during adipo-
cyte differentiation of mBMSCAdipo, were annotated according to their
molecular function, as osteogenic and adipogenic-related genes, respec-
tively (supplementary Tables 3 & 4). From the whole data set, we iden-
tiﬁed all the CDmarkers expressed bymBMSCBone (71 CDmarkers) and
mBMSCAdipo (70 CD markers). Comparing the expression levels of CD
markers at baseline in mBMSCBone versus mBMSCAdipo revealed the ex-
pression of a number of canonical CDmarkers characteristic of BMSCs to
be expressed at similar level in both cell lines (Table 1). Some of these
CD markers are known markers for BMSCs e.g. CD10, CD29, CD63,
CD146, CD140a and some are new markers e.g. CD47, CD59, CD203,
CD227. To identify a panel of CD markers associated with commitment
to osteoblastic and adipocytic lineages, we selected CDmarkers that are
expressed either in mBMSCBone or mBMSCAdipo during differentiation.
Using this criterion, we identiﬁed CD markers that can possibly deﬁne
osteoblastic progenitors (Fig. 1B) or adipocytic progenitors (Fig. 1C).
Fig. 1. Identiﬁcation of predictive CDmarkers for osteoblasts and adipocytes. (A) Unipotent differentiation capacity of mBMSCBone and mBMSCAdipo, as shown by Alizarin red staining for
matrix mineralization, Oil Red O staining for adipocyte differentiation and in vivo ectopic bone formation. (B) Microarray data showing osteoblastic CDmarkers expressed exclusively in
mBMSCBone cell line and (C) adipocytic CDmarkers expressed exclusively inmBMSCAdipo. The expression patterns of the candidateswere presented as fold change over control at different
time points of either osteoblast or adipocyte differentiation (d0, d3, d6 & d10).
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sis for selected CDmarkers inmBMSCBone,mBMSCAdipo and primary cul-
tured mBMSCs. As shown in Fig. 2 A&B, FACS analysis conﬁrmed the
presence of Sca-1, CD29, CD105, CD45 and CD140a in mBMSCBone,
mBMSCAdipo and mBMSCs. Consistent with the transcriptome data(Fig. 1B), FACS analysis revealed higher expression of CD34 and CD200
by mBMSCBone versus mBMSCAdipo (Fig. 2A&B). Both CD34 and CD200
were expressed by primary mBMSCs. However, the levels of expression
as estimated byMFI were 6 fold higher for CD34 compared with CD200.
Based on these data, we chose CD34 for further studies.
Table 1
List of commonly expressed CD markers in mBMSCBone and mBMSCAdipo cell lines.
CD
marker
Alternative
name
Full name
CD1d1 CD1d1 CD1d1 antigen
CD9 CD9 CD9 antigen
CD10 MME Membrane metallo-endopeptidase
CD29 ITGβ1 Integrin beta 1 (ﬁbronectin receptor beta)
CD47 IAP Integrin associated protein
CD49a ITGα1 Integrin alpha 1
CD49e ITGα5 Integrin alpha 5 (ﬁbronectin receptor alpha)
CD59a CD59a CD59 antigen
CD63 LAMP Lysosomal-associated membrane protein
CD71 TFRC1 Transferrin receptor protein 1
CD81 TAPA-1 Target of the antiproliferative antibody 1
CD87 uPA-R Urokinase-type plasminogen activator receptor
CD97 CD97 CD97 antigen
CD104 ITGβ4 Integrin, beta 4
CD106 VCAM-1 Vascular cell adhesion molecule 1
CD107b LAMP-2 Lysosomal-associated membrane protein 2
CD112 PRR Poliovirus receptor-related 2 (herpesvirus entry
mediator B)
CD120a TNFRI Tumor necrosis factor receptor superfamily, member 1
CD123 IL-3Ra Interleukin 3 receptor, alpha chain
CD138 SDC1 Syndecan 1
CD140a PDGFRa Platelet-derived growth factor receptor, alpha polypeptide
CD140b PDGFRb Platelet-derived growth factor receptor, beta polypeptide
CD146 MCAM Melanoma cell adhesion molecule
CD151 CD151 CD151 antigen
CD164 CD164 CD164 antigen
CD203c ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase
CD222 IGF2R Insulin-like growth factor 2 receptor
CD225 IFITM1 Interferon induced transmembrane protein 1
CD230 PRNP Prion protein
CD248 CD248 CD248 antigen
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We ﬁrst investigated mRNA expression of CD34 during osteoblast
differentiation of mouse stromal cell line ST2, mBMSCBone and primary
mBMSCs. In all three BMSCs cell lines, CD34 was found to be down reg-
ulated during osteoblast differentiation (Fig. 2C), suggesting that CD34
is expressed in osteoprogenitors and not mature osteoblastic cells.
Thereafter, we carried out FACS sorting of CD34− and CD34+ popula-
tions from cultured primary mBMSCs (Fig. 3A) and compared their CD
marker expression, cellular morphology and differentiation potential.
Both CD34− and CD34+ populations expressed comparable levels of
Sca-1 and CD140a, while CD146 was exclusively expressed by CD34+
cells (Fig. 3B). Quantitative cell morphology using high content imaging
analysis revealed a larger cytoplasmic area and reduced roundness of
CD34+ cells compared to CD34− (Fig. 3C).
3.3. Increased osteogenic potential of CD34+ mBMSCs in vitro and in vivo
CD34+ mBMSCs exhibited enhanced osteoblastic differentiation ca-
pacity compared with CD34− cells or non-sorted parental primary
mBMSCs as assessed by increased levels of ALP activity and formation
of mineralized matrix visualized by Alizarin red staining (Fig. 4A&B).
Gene expression levels of early (Runx2,Msx2, Dlx5, and Alp) and late os-
teoblastic markers (Oc, Opn and Bsp) were signiﬁcantly up-regulated
in CD34+ cells compared with CD34− cells (Fig. 4C). Furthermore,
real time PCR-based array analysis of the expression of 84 osteoblast-
related genes in CD34+ and CD34− cells at baseline revealed up-
regulation of 70% of osteogenic genes in CD34+ cells compared with
CD34− cells (3 folds, p b 0.05) (supplementary Table 5). This conﬁrms
enrichment in the osteoblastic molecular signature in CD34+ cells.
We also implanted both CD34+ cells and CD34− cells; mixed with
hydroxyapatite-tricalcium phosphate subcutaneously in immune-
deﬁcient mice for two months. No hematopoietic-supportive stromawas observed in the implants (Fig. 4D). Quantitative histological analy-
sis of implants revealed 11.6 fold increase in the heterotopic bone
formed by CD34+ cells compared to CD34− cells (p b 0.005) (Fig. 4D).
3.4. Reduced adipogenic potential of sorted CD34+ mBMSCs
Adipocyte differentiationwas evaluated by determining the number
of oil red O stained mature lipid ﬁlled adipocytes as well as gene ex-
pression levels of adipogenic markers. As shown in Fig. 5A&B, CD34+
BMSCs exhibited reduction in the number of mature adipocytes
formed (p b 0.0001) as well as signiﬁcant reduction in early (Pparγ2
and C/ebpα) and late (aP2, Apm1, Lpl) adipocytic markers as compared
to CD34− BMSCs.
4. Discussion
It is increasingly appreciated that cultured primary BMSCs are
heterogeneous with respect to their differentiation potential and that
these cultures contain multipotent BMSCs as well as lineage commit-
ted precursors (Post et al., 2008). Deﬁning the cellular and molecular
phenotype of lineage committed progenitors has been hampered by
the absence of appropriate cell models for studying their biology.
In the present study, we employed two committed progenitor cells
that have been extensively characterized in our laboratory. Their
progenitor phenotype is based on distinct cellular morphology and lin-
eage restricted differentiation capacity in vitro and in vivo (Post et al.,
2008) (Taipaleenmaki et al., 2011). Employing these two cell models,
we identiﬁed a number of core CD markers that deﬁne mBMSC and
CD markers associated with lineage commitment to osteoblastic
or adipocytic cells. In addition, we demonstrated a strategy whereby
one of these markers: CD34 can be employed to isolate prospectively
a population of osteoprogenitors. Our studies demonstrate the feasibil-
ity of this approach to dissect the cellular heterogeneity of cultured
BMSCs.
We identiﬁed a number of CD markers that are expressed in both
osteoprogenitor and adipoprogenitor cells and thus can be employed
as coremarkers of the BMSCs phenotype. Our data corroborate previous
studies that employed alternative technologies to identify markers
for multipotent BMSCs. Comparing gene expression and FACS analysis
of osteoprogenitor and adipoprogenitor cells, we have identiﬁed
CD markers that are exclusively associated with either the osteoblastic
or adipocytic phenotype. The adipocytic phenotype-associated CD
markers included CD53, CD80, CD141, CD134 and CD212. Only CD141
has previously been demonstrated to be expressed in human adipose
tissue (Ryynanen et al., 2014). On the other hand, osteoblastic
phenotype-associated CD marker included CD54, CD34, CD200, CD132
and CD227. Among these, CD54, CD73, CD34 and CD200 markers have
previously been reported to be expressed in osteoblasts (Reyes-Botella
et al., 2000; Takedachi et al., 2012; Ode et al., 2013; Delorme et al.,
2008). Reyes-Botella et al. reported the expression of CD54 in cultured
human osteoblasts isolated from normal mandibular bone. Human
osteoblasts express CD73 and human periosteal osteoblasts stain posi-
tively for CD73 (Ode et al., 2013). Cell sorting of CD34+/CD38+ cells
from human BMSCs identify an osteoprogenitors that has the ability
to differentiate into functional osteoblasts in culture (Chen et al.,
1997). Additionally, CD200+ cells loaded on biphasic calcium phos-
phate (MBCP) ceramic disks and implanted subcutaneously in nude
mice, showed higher ability for bone formation compared with un-
sorted cells (Delorme et al., 2008). The biological role of CD132 and
CD227 markers are not known.
We have identiﬁed CD34 as a potential marker for murine
osteoprogenitor cells. CD34 is a cell surface glycoprotein that functions
as an adhesion molecule and is commonly expressed on early hemato-
poietic stem cells (HSC) and their progeny as well as vascular endothe-
lial cells (Krause et al., 1996; Muller et al., 2002). CD34 expression
has been detected in a subset of human bone marrow stromal cells
Fig. 2. Expression of CD34 by mBMSCs. CD marker proﬁle of mBMSC cell lines including, primary mBMSCs, mBMSCBone and mBMSCAdipo. (A) FACS analysis of Sca-1, CD29, CD34, CD73,
CD105, CD45, CD140a and CD200was performed at baseline. (B) Themeanﬂuorescence intensity (MFI) of the expressed CDmarkers. (C) Real time PCR analysis of CD34mRNAexpression
during osteoblast differentiation of primarymBMSCs, mBMSCBone and stromal cells ST2. Data aremean± SD of three independent experiments. ns= not signiﬁcant, *pb 0.05, **p b 0.005
and ***p b 0.0001 compared to primary mBMSCs. #p b 0.05, and ###p b 0.0001 as compared between mBMSCBone and mBMSCAdipo.
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stromal cells (Garcia-Pacheco et al., 2001) and human adipose tissue
derived stromal cells (ADSCs) (Mitchell et al., 2006). Interestingly, cul-
tured human BMSCs were considered negative for CD34 expression by
the International Society for Cellular Therapy (Dominici et al., 2006).
However, several lines of evidence suggest that CD34 deﬁnes a sub-
population of BMSCs. First, studies that reported negative expression
of CD34 in BMSCs examined cultured BMSCs on plastic surfaces (Lin
et al., 2012) which may explain the loss of CD34 expression as it has
been reported in cultured expanded BMSCs from human bone marrow(Kaiser et al., 2007), adipose tissue (Planat-Benard et al., 2004) and
thymus (Mouiseddine et al., 2008). Second, sorted CD34+ from freshly
isolated human bone marrow showed high frequency for colony-
forming unit-ﬁbroblast (CFU-F) formation which is a functional marker
of multipotent BMSCs (Kaiser et al., 2007). Third, the development
of Stro-1 antibody that identiﬁes multipotent human BMSCs, was
developed based on immunization with human CD34+ BMSC fraction
(Simmons and Torok-Storb, 1991; Ning et al., 2011). Finally, our own
data presented in the current manuscript demonstrate that CD34+ is
enriched in committed osteoprogenitors. Previous studies and our own
Fig. 3.CD34 as a selectivemarker for osteoprogenitors cells. FACS cell sorting of CD34− and CD34+ derived from primarymBMSCs. (A) Gating strategy used in sorting the negative and the
positive populations of CD34. The gates were set according to the isotype control of CD34 Ab. (B). FACS analysis of the non-sorted primary mBMSCs, sorted CD34− and CD34+ for known
BMSC markers. The isotype controls represented in red line histogram, dark blue for the non-sorted mBMSCs, green for CD34− and light blue for CD34+. (C) Cell morphology analysis by
high content imaging Operetta® system of the sorted populations comparedwith the non-sorted cells. Scale bars indicate 100 μm.Data aremean± SD of three independent experiments.
ns = not signiﬁcant, *p b 0.05, **p b 0.005 and ***p b 0.0001 compared to non-sorted cells. #p b 0.05 and ##p b 0.005 as compared between CD34+ and CD34− cell populations.
455B.M. Abdallah et al. / Stem Cell Research 15 (2015) 449–458demonstrate that CD34 expression is rapidly down regulated in cultured
BMSCs and thus it is more suitable for isolating osteoprogenitors from
freshly isolated bone marrow mononuclear cells (Sato et al., 1999;
Zanjani et al., 1998; Cao et al., 2005).Comparing CD markers expression between CD34+ and CD34−
mBMSCs revealed similar pattern of expression of CD markers known
to be expressed by BMSCs. Interestingly, CD146 was enriched in
CD34+ cells. CD146 has been identiﬁed as a stemness marker for
Fig. 4. CD34+mBMSCs have increased osteogenic differentiation capacity in vitro and in vivo. Osteoblast differentiation of FACS sorted CD34+ versus CD34− cell populations derived from
primary mBMSCs. (A) Cells were induced to differentiate into osteoblastic lineage. Alkaline phosphatase (ALP) activity was measured at d6 and cytochemical staining was performed at
d12 of osteoblast differentiation. (B) Quantiﬁcation of Alizarin red staining for matrix mineralization at d12 post-osteoblast induction. (C) Real-time PCR analysis of osteoblast gene
markers: Runt-related transcription factor 2 (Runx2), Msh homeobox (Msx2), Bone Sialoprotein (Bsp) distal-less homeobox 5 (Dlx5), alkaline phosphatase (Alp) and osteopontin (Opn)
and osteocalcin (Oc). (D) In vivo ectopic bone formation by implanted CD34+ and CD34− cells. Histological sections of implants with cells after 8 weeks of the implantation stained
with H&E. Bone histomorphometric analysis of total bone area per total area of the implants. B = Bone, HA = Hydroxyapatite. Scale bars indicate 100 μm. Data are mean ± SD
of three independent experiments. *p b 0.05, **p b 0.005 and ***p b 0.0001 as compared between CD34+ and non-sorted cells. #p b 0.05, ##p b 0.005 and ###p b 0.0001 as compared
between CD34+ and CD34− cell populations.
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in vivo (Sorrentino et al., 2008; Sacchetti et al., 2007; Ulrich et al.,
2015). We have previously shown that CD146 is enriched in hBMSCs
clones with high bone forming capacity (Larsen et al., 2010). Inter-
estingly, CD146 failed to isolate cells with the BMSCs phenotype
(Chou et al., 2012). Thus, our data suggest CD146 expression is not
sufﬁcient to identify murine BMSCs, but it can be employed as an ad-
ditional CD marker, in combination with CD34 to isolate bone marrow
osteoprogenitors.CD34+ BMSCs formed heterotopic bone in vivo which corroborate
their enrichment in osteoprogenitors. While in the present study,
we employed CD34 as a marker that deﬁnes a speciﬁc lineage within
BMSCs, it is plausible that CD34 plays a role in osteoblast differentia-
tion. CD34 plays an important role in hematopoietic stem cell (HSC) bi-
ology as demonstrated in CD34 deﬁcient mice that exhibits enhanced
proliferation and blocked differentiation of hematopoietic progenitor
cells (Nielsen and McNagny, 2008). Few studies have investigated the
role of CD34 in BMSCs biology (Lin et al., 2012). Comparing CD34−
Fig. 5. CD34+ mBMSC has reduced adipogenic differentiation capacity. Adipocyte differentiation capacity of FACS sorted CD34+ versus CD34− cells derived from primary mBMSCs.
(A) Cells were differentiated into adipocyte by culturing in adipocyte induction medium and stained for lipid droplets with Oil Red O. Scale bars 100 μm. The efﬁciency of adipocyte dif-
ferentiation was quantiﬁed by the quantiﬁcation of Oil Red O dye at 490 nm. (B) Quantitative real time PCR for adipogenic markers: Peroxisome Proliferator-Activated Receptor Gamma2
(Pparγ2), CCAAT/enhancer-binding protein alpha (C/ebpα), adipocyte protein 2 (aP2), adiponectin (Apm1) and Lipoprotein lipase (Lpl). Data are mean± SD of three independent exper-
iments. ns = not signiﬁcant, **p b 0.005 and ***p b 0.0001, compared to non-sorted cells. ##p b 0.005 and ###p b 0.0001 as compared between CD34+ and CD34− cell populations.
457B.M. Abdallah et al. / Stem Cell Research 15 (2015) 449–458versus CD34+ cells derived from cultured murine BMSCs revealed
a correlation between CD34 expression and vasculogenic and angio-
genic capacity in vivo (Copland et al., 2008). Also, in humans, the
angiogenesis-related genes were signiﬁcantly enriched in CD34+ cells
(Suga et al., 2009).
5. Conclusions
We performed global microarray analysis to compare the transcrip-
tion proﬁle of CD markers expression during the course of osteoblast
and adipocyte differentiation of our previously established osteogenic-
committed mBMSCs (mBMSCBone) versus adipogenic-committed
mBMSC (mBMSCAdipo) respectively. Our data provide a set of CD
markers that distinguish osteoprogenitor versus adipoprogenitor
populations derived from mBMSCs. Among these markers, we have
identiﬁed CD34 as a potential single surface marker for isolating a ho-
mogenous population of osteoprogenitors from mouse BMSCs.Conﬂicts of interest
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